Titel och upphov Advances in biology and treatment of glioblastoma
Utgivning, distribution etc.
National Library of Medicine (NLM) klassifikationskod
DDC klassifikationskod (Dewey Decimal Classification)
Fysisk beskrivning
Serietitel - ej biuppslagsform
Anmärkning: Allmän
Anmärkning: Innehåll Preface; Contents; Author Biography; Chapter 1: Maximal Safe Resection in Glioblastoma: Use of Adjuncts; 1.1 Introduction; 1.2 Preoperative Investigations; 1.2.1 Magnetic Resonance Imaging; 1.2.2 Functional MRI; 1.2.3 Magnetoencephalography; 1.2.4 Navigated Transcranial Magnetic Stimulation; 1.2.5 Diffusion Tensor Imaging; 1.2.6 Deformable Anatomic Templates; 1.3 Intraoperative Adjuncts; 1.3.1 Intraoperative Image Guidance Techniques; 1.3.2 5-Aminolevulinic Acid; 1.3.3 Functional Cortical and Subcortical Mapping; 1.3.4 Principles of Direct Electrical Stimulation. 1.3.5 Motor Mapping and Monitoring1.3.5.1 Somatosensory Evoked Potentials; 1.3.5.2 Motor Evoked Potentials; 1.3.5.3 Cortical Stimulation; 1.3.5.4 Subcortical Stimulation; 1.3.6 Language Mapping; 1.3.7 Resection Principles; 1.4 Conclusion; References; Chapter 2: Molecular Pathology of Glioblastoma- An Update; 2.1 Introduction to Adult Diffuse Gliomas and Glioblastoma with Emphasis on Changing Concepts; 2.2 ISN Haarlem Guidelines and Evolution of WHO 2016; 2.3 WHO 2007 Classification Versus 2016 Classification w.r.t Glioblastoma (Table 2.2). 2.4 Glioblastoma: Gross Pathology, Histomorphology and the New Definitions2.4.1 Glioblastoma, IDH-Wild Type; 2.4.2 Glioblastoma, IDH Mutant (Fig. 2.7); 2.5 Molecules That Define Glioblastoma in Detail; 2.5.1 IDH Mutations; 2.5.2 O6-Methyl Guanine DNA Methyl Transferase (MGMT) Gene Promoter Methylation; 2.5.3 ATRX Mutation; 2.5.4 TP53 Mutation; 2.5.5 TERT Promoter Mutation; 2.5.6 Cytogenetic Abnormalities; 2.5.7 EGFR Amplification and Mutation; 2.5.8 PTEN Mutation; 2.5.9 Platelet Derived Growth Factor Receptor Alpha(PDGFRA); 2.5.10 Neurofibromatosis Type 1 Gene (NF1)Inactivation. 2.5.11 Signaling Pathways Altered in Glioblastoma:2.6 Molecular Biology of Recurrence in Glioblastoma Tumors; 2.7 Summary; 2.8 Clinical Trials; 2.9 Need of the Hour; References; Chapter 3: Current Therapies and Future Directions in Treatment of Glioblastoma; 3.1 Introduction; 3.2 Newly Diagnosed Glioblastoma; 3.2.1 Surgical Resection; 3.2.2 First Line Therapy for Newly Diagnosed GBM; 3.3 Recurrent Glioblastoma; 3.4 Glioblastoma in Older Adults; 3.5 Gliomatosis Cerebrii; 3.6 Targeted Agents in Treatment of GBM; 3.6.1 EGFR Inhibitors; 3.6.2 PI3K and mTOR Inhibitors. 3.6.3 VEGF and VEGFR Inhibitors3.7 Biological Agents in Clinical Trials Against Glioblastoma; 3.7.1 Virus-Based Therapies; 3.7.2 Immunotherapies; 3.7.2.1 Immune Checkpoint Inhibitors; 3.7.2.2 Genetically Engineered T-cells; 3.8 Conclusions; References; Chapter 4: Recent Advances for Targeted Therapies in Glioblastoma; 4.1 Recent Advances for Targeted Therapies in Glioblastoma; 4.2 The Cancer Genome Atlas; 4.3 Tumor Protein P53 Signaling Pathway; 4.4 Retinoblastoma (Rb) Pathway; 4.5 Receptor Tyrosine Kinases Pathway; 4.5.1 VEGFR; 4.5.2 EGFR; 4.5.3 PDGFR; 4.5.4 PI3K/AKT/PTEN/mTOR.
Anmärkning: Innehållsbeskrivning, sammanfattning This volume covers the most important areas of glioblastoma - surgical resection, molecular pathology, targeted therapies, cancer stem cells, the role of DNA methylation, targeted sequencing for personalized therapy, animal models and advances in pediatric glioblastoma. Chapter authors are junior and senior investigators, who are well established in their particular areas and include neurosurgeons, neuropathologists, neurooncologists and basic scientists.
Term
Genre/Form
Personnamn
Annat medium Print version: ISBN 9783319568195 ISBN 3319568191
Seriebiuppslag under titel
Elektronisk adress och åtkomst (URI) http://link.springer.com/10.1007/978-3-319-56820-1
ISBN
*00000000cam a2200000Mi 4500
*00178898
*00520181120085415.9
*006m o d
*007cr |n|||||||||
*008170705s2017 sz o 001 0 eng d
*019 $a993040210$a996431657$a999538845$a1005838345$a1011899842$a1048131784
*020 $a9783319568201$q(electronic bk.)
*020 $a3319568205$q(electronic bk.)
*020 $z9783319568195
*020 $z3319568191
*0247 $a10.1007/978-3-319-56820-1$2doi
*029 $aAU@$b000060467368
*029 $aGBVCP$b89336407X
*035 $a(OCoLC)992779231$z(OCoLC)993040210$z(OCoLC)996431657$z(OCoLC)999538845$z(OCoLC)1005838345$z(OCoLC)1011899842$z(OCoLC)1048131784
*035 $a(OCoLC)ocn992779231
*040 $aYDX$beng$epn$cYDX$dN$dEBLCP$dGW5XE$dN$dUAB$dYDX$dOCLCO$dAZU$dUPM$dOCLCO$dIOG$dOCLCO$dMERER$dESU$dOCLCQ$dCOO$dOCLCQ$dOCLCO$dOCLCA$dU3W$dCAUOI$dOCLCF$dOCLCO$dKSU$dVT2$dOCLCO
*049 $aMAIN
*050 4$aRC280.B7
*060 4$aWL 358
*072 7$aHEA$x039000$2bisacsh
*072 7$aMED$x014000$2bisacsh
*072 7$aMED$x022000$2bisacsh
*072 7$aMED$x112000$2bisacsh
*072 7$aMED$x045000$2bisacsh
*072 7$aMJCL$2bicssc
*08204$a616.99/481$223
*24500$aAdvances in biology and treatment of glioblastoma /$cKumaravel Somasundaram, editor.
*260 $aCham :$bSpringer,$c2017.
*300 $a1 online resource.
*336 $atext$btxt$2rdacontent
*337 $acomputer$bc$2rdamedia
*338 $aonline resource$bcr$2rdacarrier
*347 $atext file$bPDF$2rda
*4901 $aCurrent cancer research
*500 $aIncludes index.
*5050 $aPreface; Contents; Author Biography; Chapter 1: Maximal Safe Resection in Glioblastoma: Use of Adjuncts; 1.1 Introduction; 1.2 Preoperative Investigations; 1.2.1 Magnetic Resonance Imaging; 1.2.2 Functional MRI; 1.2.3 Magnetoencephalography; 1.2.4 Navigated Transcranial Magnetic Stimulation; 1.2.5 Diffusion Tensor Imaging; 1.2.6 Deformable Anatomic Templates; 1.3 Intraoperative Adjuncts; 1.3.1 Intraoperative Image Guidance Techniques; 1.3.2 5-Aminolevulinic Acid; 1.3.3 Functional Cortical and Subcortical Mapping; 1.3.4 Principles of Direct Electrical Stimulation.
*5058 $a1.3.5 Motor Mapping and Monitoring1.3.5.1 Somatosensory Evoked Potentials; 1.3.5.2 Motor Evoked Potentials; 1.3.5.3 Cortical Stimulation; 1.3.5.4 Subcortical Stimulation; 1.3.6 Language Mapping; 1.3.7 Resection Principles; 1.4 Conclusion; References; Chapter 2: Molecular Pathology of Glioblastoma- An Update; 2.1 Introduction to Adult Diffuse Gliomas and Glioblastoma with Emphasis on Changing Concepts; 2.2 ISN Haarlem Guidelines and Evolution of WHO 2016; 2.3 WHO 2007 Classification Versus 2016 Classification w.r.t Glioblastoma (Table 2.2).
*5058 $a2.4 Glioblastoma: Gross Pathology, Histomorphology and the New Definitions2.4.1 Glioblastoma, IDH-Wild Type; 2.4.2 Glioblastoma, IDH Mutant (Fig. 2.7); 2.5 Molecules That Define Glioblastoma in Detail; 2.5.1 IDH Mutations; 2.5.2 O6-Methyl Guanine DNA Methyl Transferase (MGMT) Gene Promoter Methylation; 2.5.3 ATRX Mutation; 2.5.4 TP53 Mutation; 2.5.5 TERT Promoter Mutation; 2.5.6 Cytogenetic Abnormalities; 2.5.7 EGFR Amplification and Mutation; 2.5.8 PTEN Mutation; 2.5.9 Platelet Derived Growth Factor Receptor Alpha(PDGFRA); 2.5.10 Neurofibromatosis Type 1 Gene (NF1)Inactivation.
*5058 $a2.5.11 Signaling Pathways Altered in Glioblastoma:2.6 Molecular Biology of Recurrence in Glioblastoma Tumors; 2.7 Summary; 2.8 Clinical Trials; 2.9 Need of the Hour; References; Chapter 3: Current Therapies and Future Directions in Treatment of Glioblastoma; 3.1 Introduction; 3.2 Newly Diagnosed Glioblastoma; 3.2.1 Surgical Resection; 3.2.2 First Line Therapy for Newly Diagnosed GBM; 3.3 Recurrent Glioblastoma; 3.4 Glioblastoma in Older Adults; 3.5 Gliomatosis Cerebrii; 3.6 Targeted Agents in Treatment of GBM; 3.6.1 EGFR Inhibitors; 3.6.2 PI3K and mTOR Inhibitors.
*5058 $a3.6.3 VEGF and VEGFR Inhibitors3.7 Biological Agents in Clinical Trials Against Glioblastoma; 3.7.1 Virus-Based Therapies; 3.7.2 Immunotherapies; 3.7.2.1 Immune Checkpoint Inhibitors; 3.7.2.2 Genetically Engineered T-cells; 3.8 Conclusions; References; Chapter 4: Recent Advances for Targeted Therapies in Glioblastoma; 4.1 Recent Advances for Targeted Therapies in Glioblastoma; 4.2 The Cancer Genome Atlas; 4.3 Tumor Protein P53 Signaling Pathway; 4.4 Retinoblastoma (Rb) Pathway; 4.5 Receptor Tyrosine Kinases Pathway; 4.5.1 VEGFR; 4.5.2 EGFR; 4.5.3 PDGFR; 4.5.4 PI3K/AKT/PTEN/mTOR.
*520 $aThis volume covers the most important areas of glioblastoma - surgical resection, molecular pathology, targeted therapies, cancer stem cells, the role of DNA methylation, targeted sequencing for personalized therapy, animal models and advances in pediatric glioblastoma. Chapter authors are junior and senior investigators, who are well established in their particular areas and include neurosurgeons, neuropathologists, neurooncologists and basic scientists.
*5880 $aPrint version record.
*590 $aSpringerLink$bSpringer Medicine eBooks 2017 English+International
*650 0$aGliomas.
*650 0$aGliomas$xTreatment.
*650 7$aHEALTH & FITNESS$xDiseases$xGeneral.$2bisacsh
*650 7$aMEDICAL$xClinical Medicine.$2bisacsh
*650 7$aMEDICAL$xDiseases.$2bisacsh
*650 7$aMEDICAL$xEvidence-Based Medicine.$2bisacsh
*650 7$aMEDICAL$xInternal Medicine.$2bisacsh
*650 7$aGliomas.$2fast$0(OCoLC)fst00943446
*650 2$aGlioblastoma$xtherapy.
*655 4$aElectronic books.
*7001 $aSomasundaram, Kumaravel,$eeditor.
*77608$iPrint version:$z9783319568195$z3319568191$wIMP(OCoLC)(OCoLC)978290042
*830 0$aCurrent cancer research.
*85640$uhttp://link.springer.com/10.1007/978-3-319-56820-1
*938 $aEBL - Ebook Library$bEBLB$nEBL4894875
*938 $aEBSCOhost$bEBSC$n1547588
*938 $aYBP Library Services$bYANK$n14669087
*994 $a92$bSESKS
^
Det finns inga omdömen till denna titeln.
Klicka här
för att vara den första som skriver ett omdöme.